AlphaFold Unofficial (@alphafold.bsky.social)

'An AlphaFold 4'-scientists marvel at DeepMind drug spin-off's exclusive new AI I agree my information will be processed in accordance with the Scientific American and Springer Nature Limited Privacy Policy . We leverage third party services to both verify and deliver email. By providing your email address, you also consent to having the email address shared with third parties for those purposes. Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful artificial-intelligence model — and they’re keeping it all to themselves. Isomorphic Labs, based in London, touted the capacities of its ‘drug-discovery engine’ — which it calls IsoDDE — in a 27-page technical report, released on 10 February. Achievements, including precise predictions of how proteins interact with potential drugs and antibody structures, have impressed scientists working in the field. Yet unlike the AlphaFold AI systems for predicting protein structure — which were made accessible to other researchers and described in depth in journal articles — IsoDDE is proprietary, and the technical paper offers scant insight into how to achieve similar results. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure... https://www.scientificamerican.com/article/an-alphafold-4-scientists-marvel-at-deepmind-drug-spin-offs-exclusive-new-ai/